Back to search results
NCT04110522

Psoriatic Arthritis D2P Screening

Active, Not Recruiting
NAAges 18+InterventionalScreening
Jessica Walsh
~18,000 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:Direct to patient PsA Screening Questionnaire

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of patients with a new PsA diagnosis
Measured over 6 months
+1 more outcome measured

Conditions

Psoriatic Arthritis

Explore related trials

PsoriasisPsoriatic Arthritis

Where it's being run

2 sites across 2 states
Pennsylvania1
Utah1

Study leadership

  • Jessica Walsh, M.D. · PRINCIPAL_INVESTIGATOR · University of Utah

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have an International Classification of Diseases (ICD) code diagnosis of psoriasis but without a confirmed diagnosis of Psoriatic Arthritis prior to study initiation
Be age 18 or older
Be geographically located within a reasonable proximity to the Rheumatology study site

Exclusion

Have psoriasis and a confirmed diagnosis of psoriatic arthritis made or confirmed by a rheumatologist

What this trial measures

  • Percentage of patients with a new PsA diagnosis6 months

    The percentage of psoriasis patients with a new diagnosis of PsA will be compared between the Experimental Arms and the Control Arm, and compared between the two Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral)

  • Symptom duration6 months

    Average duration of baseline symptoms prior to PsA diagnosis in the Experimental Arms (intervention with direct access to rheumatologist and intervention with standard of care referral) will be compared to the average duration of baseline symptoms prior to PsA diagnosis in the Control Arm